Comparator and Ancillary Medicine Supply

The design of a clinical trial often includes, alongside the investigational product, a comparator and medicines safeguarding patient safety. These two categories follow rules as rigorous as the IMP's but different from it: the comparator is sometimes a product licensed on the Turkish market that must be over-labelled for blinding; sometimes it is imported and carries its own permit chain. Ancillary medicines, even though defined in the protocol, do not carry investigational product status and are procured differently. The sourcing decision is a regulatory and quality decision, not a cost decision: a comparator arriving through the wrong channel puts the trial's validity and patient safety at risk together. This article explains the sourcing routes for comparators, the rules of blinding and over-labelling, the status of ancillary medicines and the accountability requirements of both categories. A practical frame is offered for sponsors, CROs and clinical supply teams.

Who is this for?

This guide is for every role touching comparator and ancillary medicine supply. Sponsor teams designing the protocol must know the sourcing strategy early, because the choice reflects into the trial file and the labelling. CROs and clinical supply units plan purchasing, import, blinding and site distribution. Procurement teams need to know from which channel licensed products may be bought and how supplier qualification is verified. Customs and import owners track the document requirements of the import route. Quality units audit the over-labelling operations and the blinding records. Site teams and pharmacists manage the prescribing and dispensing flow of ancillary medicines. Before an audit the question is the same for everyone: where did this product come from, who handled it and where is the record. The answer must sit ready in the corporate file.

Which products does it cover?

The scope covers every product used in the comparator arm and the supportive-care medicines defined in the protocol. The comparator is the reference tested against the investigational product: it can be the originator licensed on the local market, a generic equivalent or a form sourced from abroad. Placebo manufactures belong to this chain as well; they are matched in appearance to the comparator. Ancillary medicines are products of the trial's subject matter but defined for clinical need in the protocol: supportive treatment, avoidance medicines or products foreseen for event management. The line between them matters: the comparator is one of the trial's evaluation arms and is handled like an investigational product; the ancillary medicine is given to the patient within standard care. The status decision is defined in the protocol and reflected verbatim into the sourcing file. As a product family all of them sit in the pharmaceutical GTİP group; but the customs and document chain differs by sourcing route.

When does it apply?

The sourcing rules apply to every trial with a comparator arm, but some scenarios sharpen the process. Where a product licensed in Türkiye is used, procurement must run from the authorised distributor, preserving invoice traceability; parallel or informal channels are not accepted. The import route opens when the licensed product is unavailable, interrupted or not offered in a suitable strength on the local market. Where blinding is required, over-labelling comes onto the agenda: the product is repacked with trial labelling, and the operation's records are kept. In multinational trials the sponsor's central supply is assessed together with local legislation; each country carries its own import and labelling conditions. On the ancillary side, procurement of protocol-defined products rests on prescription; site-level purchases must be bound to procedures, not corporate cards. Supplier changes, product interruptions and batch differences must always be carried into change management.

Legal framework and authority

The frame comes from the clinical trials legislation and the pharmaceutical distribution rules. Comparators enter the scope of the clinical trials legislation as evaluation arms of the trial; their procurement, labelling and accountability requirements are set in that frame. The distribution of licensed products is subject to the traceability and distribution rules for medicines for human consumption; these products may be sourced only through authorised channels. The import of unlicensed products within a trial is tied to the trial approval and the competent authority's processes; on the customs side the pharmaceutical GTİP control applies. The competent authority is TİTCK: it evaluates trial applications, sets the rules for product supply and audits traceability. Customs transactions run through Ministry of Trade administrations. The controlled-environment and record requirements for blinding and over-labelling operations are the subject of quality systems. Current guides and regulations must be tracked on TİTCK's official pages, and the sourcing strategy seated on the current state of the law.

Step-by-step process

1. Clarify every product's status in the protocol: comparator or ancillary medicine; is blinding required, in which strength and form.
2. Research the licensing status on the local market: is the product licensed, in which strength, who is the authorised distributor, how sustainable is supply.
3. Choose the sourcing route and write its rationale: local purchase, import within the trial frame or sponsor supply; let the decision align with protocol and budget.
4. On the import route, build the permit chain: trial approval, importer designation, customs document set and cold chain plan.
5. If blinding is required, plan the operation: controlled environment, trial label, appearance matching and unopened blinding records.
6. Verify supplier qualification: authorised distributor documents, invoice chain, batch and expiry verification.
7. Define shipment and receipt checks: quantity, batch, label, temperature record and deviation flow.
8. Plan site distribution: needs-based quantities, delivery records and return procedure.
9. Operate accountability from day one: reconciliation of quantities received, distributed, returned and destroyed.

Document checklist

• Protocol section showing product statuses, in its current version.
• Comparator's licensing status and authorised distributor information.
• Purchase documents: order, invoice, delivery record; proof of authorised channel.
• Import file: trial approval reference, importer designation, customs documents.
• Product certificates and analysis documents, batch by batch.
• Blinding plan: over-labelling instruction, environment conditions, record layout.
• Trial label mock-ups and approvals, with Turkish information.
• Cold chain records and transport verification documents.
• Site delivery and return minutes.
• Accountability tables and reconciliation records.

Parties and responsibilities

Responsibilities shift with the product's status: with the comparator the load sits on the regulatory side, with ancillary medicines on clinical operations. The matrix should show both statuses in separate rows and be kept current in every shipment file.

Exceptions and edge cases

Edge cases are where most sourcing errors are born. The import of a product licensed on the local market is not automatically free; local procurement has priority and the import rationale must be filed. The original identity of a blinded product must be preserved through a code system; the code map must stay unopened while the trial runs. A product foreseen as an ancillary medicine can acquire investigational product status through a protocol revision; that transition rebuilds the supply chain from scratch. With generic comparators, the bioequivalence rationale must be assessed together with the statistical plan. Sourcing through parallel import channels is not accepted for trial products; traceability breaks. In patient-based rare products the quantities are person-specific and the return lanes are narrow. On product interruption, the decision to continue with an alternative strength cannot be taken without protocol and ethics committee approval. Every edge decision's written rationale is the first answer to a possible audit.

Common mistakes

The most common mistake is buying the comparator through a channel whose authorisation is undocumented; without the invoice chain the product cannot be used in the trial. The second is not filing the import rationale; the answer to why a locally licensed product was imported is not ready. The third is running blinding in an uncontrolled environment; over-labelling without records damages data reliability. The fourth is importing ancillary medicines as if they were investigational products; the status confusion produces both cost and noncompliance. The fifth is not tracking batch differences and expiry dates; short-dated stock reaches the site. The sixth is leaving accountability to the trial's end; the reconciliation stays incomplete. The seventh is not carrying supplier changes into change management; blinding and label versions fall out of step.

Important notice

This article is general information, not legal or customs advice; for the product supply of a specific trial, TİTCK legislation and current guides must govern. GTİP codes and sourcing examples mentioned here are for orientation; the GTİP examples are not binding. Sourcing strategies are subject to legislative change; official sources must be checked before any transaction.